US Stock MarketDetailed Quotes

REGN Regeneron Pharmaceuticals

Watchlist
  • 716.680
  • +2.210+0.31%
Close Dec 26 16:00 ET
  • 716.680
  • 0.0000.00%
Post 20:01 ET
78.76BMarket Cap17.73P/E (TTM)

About Regeneron Pharmaceuticals Company

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Company Profile

SymbolREGN
Company NameRegeneron Pharmaceuticals
Listing DateApr 2, 1991
Issue Price22.00
Founded1988
CEODr. Leonard S. Schleifer,M.D.,PhD
MarketNASDAQ
Employees13450
Fiscal Year Ends12-31
Address777 Old Saw Mill River Road
CityTarrytown
ProvinceNew York
CountryUnited States of America
Zip Code10591-6707
Phone1-914-847-7000

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Leonard S. Schleifer,M.D.,PhD
  • Co-Chairman of the Board, Co-President and Chief Executive Officer
  • 8.18M
  • Christopher R. Fenimore
  • Senior Vice President, Finance and Chief Financial Officer
  • --
  • Dr. George D. Yancopoulos,M.D.,PhD
  • Co-Chairman of the Board, Co-President and Chief Scientific Officer
  • 7.76M
  • Daniel P. Van Plew
  • Executive Vice President and General Manager, Industrial Operations and Product Supply
  • 8.76M
  • Joseph J. Larosa
  • Executive Vice President, General Counsel and Secretary
  • --
  • Marion McCourt
  • Executive Vice President, Commercial
  • --
  • Jason Pitofsky
  • Vice President and Controller
  • --
  • Andrew J Murphy
  • Executive Vice President, Research
  • 8.43M
  • Dr. Neil Stahl,PhD
  • Executive Vice President, Research and Development
  • --
  • Kathryn Guarini, PhD
  • Director
  • 1.03M
  • Dr. David P. Schenkein, M.D.
  • Director
  • 1.03M
  • George L. Sing
  • Independent Director
  • 724.99K
  • Dr. N. Anthony Coles, M.D.
  • Independent Director
  • 704.99K
  • Christine A. Poon
  • Lead Independent Director
  • 748.01K
  • Dr. Bonnie L. Bassler, PhD
  • Independent Director
  • 709.99K
  • Arthur Frederick Ryan
  • Independent Director
  • 724.99K
  • Dr. Michael S. Brown, M.D.
  • Independent Director
  • 728.99K
  • Dr. Joseph L. Goldstein,M.D.
  • Independent Director
  • 709.99K
  • Dr. Huda Y. Zoghbi, M.D.
  • Independent Director
  • 714.99K
  • Dr. Craig B. Thompson,M.D.
  • Independent Director
  • 247.79K
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.